올릭스

226950KOSDAQ자연과학 및 공학 연구개발업

50.0 / 100

Reference Date: 2026-06-10

Financial Score10.5 / 40

News Sentiment19.5 / 25

Momentum10.0 / 20

Disclosure10.0 / 15

AI Analysis: the high debt ratio poses financial risk, PBR raises overvaluation concerns. Plunged 21.4% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Olix is a biopharmaceutical company specializing in developing therapeutic drugs for difficult-to-treat diseases using RNA interference (RNAi) platform technology. The company leverages its proprietary 'self-delivering asymmetric siRNA (cp-asiRNA)' technology to create drug candidates targeting metabolic diseases, obesity, and cardiovascular conditions. Through technology licensing agreements with global and domestic pharmaceutical companies, including a significant deal with Eli Lilly, Olix has established a strong market presence and revenue streams.

Number of Employees

76people

Average Salary

198.2M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 62.704.0Point

PBR

17.81Industry Average 3.240.0Point

5.5x industry avg (risky)

ROE

-18.68Industry Average -32.093.5Point

Below industry avg

Debt Ratio

15.97Industry Average 7.310.0Point

2.2x industry avg (risky)

Trend 2023~20253.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲45.8% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼33.5% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -56.5% (improving, 3yr)

Detailed News Sentiment

15 totalPositive 12Neutral 3Negative 0Average Sentiment Score 78

Positive
올릭스, 지방 유전자 끄는 RNA 비만신약 원숭이서 효과 확인
올릭스의 비만 치료제 후보물질이 원숭이 실험에서 긍정적인 결과를 보여주며, 글로벌 시장 진출에 대한 기대감이 높아졌다.
Positive
올릭스 "비만약 영장류 중간 데이터서 지방 감소"
올릭스의 영장류 실험 중간 데이터에서 지방 감소 효과 확인으로 신약 개발 진전 기대.
Positive
올릭스 “비만 원숭이서 효능 확인”… 글로벌 기술이전 기대감
올릭스의 RNAi 기술을 활용한 비만치료제 개발이 원숭이 실험에서 긍정적인 결과를 보여 글로벌 기술이전 기대감이 높아졌다.

Detailed Momentum

52-week position5.0Point

52w mid range (56%)

Current 131,700Won52-week high 207,00052-week low 34,800

1-month return0.0Point

1m -21.42% (strong drop)

Volume trend5.0Point

Volume increasing

Detailed Disclosure

6 totalPositive 0Neutral 6Negative 0

Neutral주주명부폐쇄기간또는기준일설정2026-06-01
Neutral주식등의대량보유상황보고서(일반)2026-06-01
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-06-01
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-06-01
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-06-01